These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36865907)

  • 1. In patients with hemophilia, a decreased thrombin generation profile is associated with a severe bleeding phenotype.
    Verhagen MJA; van Heerde WL; van der Bom JG; Beckers EAM; Blijlevens NMA; Coppens M; Gouw SC; Jansen JH; Leebeek FWG; van Vulpen LFD; Meijer D; Schols SEM
    Res Pract Thromb Haemost; 2023 Feb; 7(2):100062. PubMed ID: 36865907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients with moderate hemophilia A and B with a severe bleeding phenotype have an increased burden of disease.
    Verhagen MJA; van Balen EC; Blijlevens NMA; Coppens M; van Heerde WL; Leebeek FWG; Rijpma SR; van Vulpen LFD; Gouw SC; Schols SEM
    J Thromb Haemost; 2024 Jan; 22(1):152-162. PubMed ID: 37813197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utility of activated partial thromboplastin time clot waveform analysis and thrombin generation test in the evaluation of bleeding phenotype in Hemophilia A.
    Dave RG; Geevar T; Mammen JJ; Vijayan R; Mahasampath G; Nair SC
    Indian J Pathol Microbiol; 2021; 64(1):117-122. PubMed ID: 33433420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-Pharmacodynamic Modelling in Hemophilia A: Relating Thrombin and Plasmin Generation to Factor VIII Activity After Administration of a VWF/FVIII Concentrate.
    Valke LLFG; Cloesmeijer ME; Mansouritorghabeh H; Barteling W; Blijlevens NMA; Cnossen MH; Mathôt RAA; Schols SEM; van Heerde WL
    Eur J Drug Metab Pharmacokinet; 2024 Mar; 49(2):191-205. PubMed ID: 38367175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation.
    Valke LLFG; Bukkems LH; Barteling W; Laros-van Gorkom BAP; Blijlevens NMA; Mathôt RAA; van Heerde WL; Schols SEM
    J Thromb Haemost; 2020 Dec; 18(12):3222-3231. PubMed ID: 32979031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining factor VIII levels and thrombin/plasmin generation: A population pharmacokinetic-pharmacodynamic model for patients with haemophilia A.
    Bukkems LH; Valke LLFG; Barteling W; Laros-van Gorkom BAP; Blijlevens NMA; Cnossen MH; van Heerde WL; Schols SEM; Mathôt RAA
    Br J Clin Pharmacol; 2022 Jun; 88(6):2757-2768. PubMed ID: 34921439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombin generation and implications for hemophilia therapies: A narrative review.
    Sidonio RF; Hoffman M; Kenet G; Dargaud Y
    Res Pract Thromb Haemost; 2023 Jan; 7(1):100018. PubMed ID: 36798897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overall hemostasis potential and aPTT-clot waveform analysis as powerful laboratory diagnostic tools for identification of hemophilia A patients with unexpected bleeding phenotype.
    Milos M; Coen Herak D; Mahmoud Hourani Soutari N; Pavic J; Zupancic-Salek S; Zadro R; Antovic JP
    Int J Lab Hematol; 2021 Apr; 43(2):273-280. PubMed ID: 32964648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bleeding phenotype of patients with moderate haemophilia A and B assessed by thromboelastometry and thrombin generation.
    Måseide RJ; Berntorp E; Nummi V; Lassila R; Tjønnfjord GE; Holme PA
    Haemophilia; 2021 Sep; 27(5):793-801. PubMed ID: 34106506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applicability of the Thrombin Generation Test to Evaluate the Hemostatic Status of Hemophilia A Patients in Daily Clinical Practice.
    Bernardo Á; Caro A; Martínez-Carballeira D; Corte JR; Vázquez S; Palomo-Antequera C; Andreu A; Fernández-Pardo Á; Oto J; Gutiérrez L; Soto I; Medina P
    J Clin Med; 2022 Jun; 11(12):. PubMed ID: 35743412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic variation in severe hemophilia A is related to endogenous thrombin potential and plasma levels of factor VII.
    Chaves DG; Fonseca FML; Araújo HCB; de Oliveira LMM; Amorim MVA; Assis Neto CC; Carvalho MDG
    Blood Coagul Fibrinolysis; 2022 Dec; 33(8):463-467. PubMed ID: 36409923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of the phenotype heterogeneity in severe hemophilia A using thromboelastography, thrombin generation, and thrombodynamics.
    Tarandovskiy ID; Balandina AN; Kopylov KG; Konyashina NI; Kumskova MA; Panteleev MA; Ataullakhanov FI
    Thromb Res; 2013 Jun; 131(6):e274-80. PubMed ID: 23611257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq
    Dargaud Y; Negrier C; Rusen L; Windyga J; Georgiev P; Bichler J; Solomon C; Knaub S; Lissitchkov T; Klamroth R
    Haemophilia; 2018 Jul; 24(4):619-627. PubMed ID: 29855112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombomodulin-modified thrombin generation after in vivo recombinant factor VIII treatment in severe hemophilia A.
    Dielis AW; Balliël WM; van Oerle R; Hermens WT; Spronk HM; Ten Cate H; Hamulyák K
    Haematologica; 2008 Sep; 93(9):1351-7. PubMed ID: 18641016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic heterogeneity in severe hemophilia.
    van den Berg HM; De Groot PH; Fischer K
    J Thromb Haemost; 2007 Jul; 5 Suppl 1():151-6. PubMed ID: 17635721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays.
    Kizilocak H; Marquez-Casas E; Malvar J; Carmona R; Young G
    Haemophilia; 2021 Sep; 27(5):730-735. PubMed ID: 34115433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B.
    Dargaud Y; Béguin S; Lienhart A; Al Dieri R; Trzeciak C; Bordet JC; Hemker HC; Negrier C
    Thromb Haemost; 2005 Mar; 93(3):475-80. PubMed ID: 15735797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
    Antovic JP; Schulman S; An SS; Greenfield RS; Blombäck M
    Scand J Clin Lab Invest; 2004; 64(8):745-51. PubMed ID: 15719893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Which tests can most effectively indicate the clinical phenotype of paediatric haemophilia patients with prophylaxis?
    Ay Y; Toret E; Gozmen S; Cubukcu D; Karapinar TH; Oymak Y; Vergin RC
    Blood Coagul Fibrinolysis; 2021 Jun; 32(4):259-265. PubMed ID: 33955860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia.
    Aymonnier K; Kawecki C; Venisse L; Boulaftali Y; Christophe OD; Lenting PJ; Arocas V; de Raucourt E; Denis CV; Bouton MC
    Blood; 2019 Nov; 134(19):1632-1644. PubMed ID: 31383642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.